- Home
- MCRB vs RFAI Comparison
MCRB vs RFAI Comparison
Compare MCRB & RFAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- RFAI
- Stock Information
- Founded
- MCRB 2010
- RFAI 2024
- Country
- MCRB United States
- RFAI Singapore
- Employees
- MCRB N/A
- RFAI N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- RFAI
- Sector
- MCRB Health Care
- RFAI
- Exchange
- MCRB Nasdaq
- RFAI NYSE
- Market Cap
- MCRB 141.9M
- RFAI N/A
- IPO Year
- MCRB 2015
- RFAI 2024
- Fundamental
- Price
- MCRB $0.72
- RFAI $10.37
- Analyst Decision
- MCRB Hold
- RFAI
- Analyst Count
- MCRB 5
- RFAI 0
- Target Price
- MCRB $4.00
- RFAI N/A
- AVG Volume (30 Days)
- MCRB 840.7K
- RFAI 10.0K
- Earning Date
- MCRB 03-13-2025
- RFAI 01-01-0001
- Dividend Yield
- MCRB N/A
- RFAI N/A
- EPS Growth
- MCRB N/A
- RFAI N/A
- EPS
- MCRB 0.00
- RFAI N/A
- Revenue
- MCRB N/A
- RFAI N/A
- Revenue This Year
- MCRB N/A
- RFAI N/A
- Revenue Next Year
- MCRB N/A
- RFAI N/A
- P/E Ratio
- MCRB $824.00
- RFAI $45.20
- Revenue Growth
- MCRB N/A
- RFAI N/A
- 52 Week Low
- MCRB $0.54
- RFAI $10.00
- 52 Week High
- MCRB $1.53
- RFAI $10.40
- Technical
- Relative Strength Index (RSI)
- MCRB 46.92
- RFAI N/A
- Support Level
- MCRB $0.69
- RFAI N/A
- Resistance Level
- MCRB $0.76
- RFAI N/A
- Average True Range (ATR)
- MCRB 0.05
- RFAI 0.00
- MACD
- MCRB 0.00
- RFAI 0.00
- Stochastic Oscillator
- MCRB 53.55
- RFAI 0.00
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.